Perraut R, Lussow A R, Gavoille S, Garraud O, Matile H, Tougne C, van Embden J, van der Zee R, Lambert P H, Gysin J
World Health Organization-Immunology Research and Training Centre, Department of Pathology, University of Geneva, Switzerland.
Clin Exp Immunol. 1993 Sep;93(3):382-6. doi: 10.1111/j.1365-2249.1993.tb08189.x.
We have previously shown in mice that antibodies can be induced to synthetic malaria peptides conjugated to mycobacterial antigens, such as purified protein derivative (PPD) or heat shock proteins (hsp), and given in the absence of adjuvants after a previous priming with bacille Calmette-Guérin (BCG). In the present study we investigated this model of immunization in the non-human primates, Saimiri sciureus monkeys. Monkeys primed with BCG subcutaneously and then immunized subcutaneously with the Plasmodium falciparum sporozoite (NANP)40 synthetic peptide conjugated to PPD or mycobacterial hsp of 65 or 70 kD, in the absence of adjuvants, produced antipeptide and anti-sporozoite IgG antibodies. Interestingly, the carrier effect of the hsp of 70 kD for the induction of anti-(NANP)40 antibodies was also observed in the absence of a previous priming with BCG. These data suggest that such a vaccination strategy may be applied to humans.
我们之前在小鼠中发现,针对与分枝杆菌抗原(如纯化蛋白衍生物(PPD)或热休克蛋白(hsp))偶联的合成疟疾肽,可以诱导产生抗体,并且在用卡介苗(BCG)进行初次免疫后,无需佐剂即可给予这些肽。在本研究中,我们在非人灵长类动物松鼠猴(Saimiri sciureus monkeys)中研究了这种免疫模型。用BCG皮下免疫的猴子,随后在无佐剂的情况下,皮下注射与PPD或65或70kD的分枝杆菌hsp偶联的恶性疟原虫子孢子(NANP)40合成肽,产生了抗肽和抗子孢子IgG抗体。有趣的是,在没有用BCG进行初次免疫的情况下,也观察到70kD的hsp对诱导抗(NANP)40抗体的载体效应。这些数据表明,这种疫苗接种策略可能适用于人类。